Abstract
With the decline incidence of rheumatic carditis, calcific aortic valve disease (CAVD) [1] has become the most common indication for surgical valve replacement in the United States and in Europe [2]. Numerous epidemiologic studies identified risk factors for CAVD, which are similar to those of vascular atherosclerosis, including smoking, male gender, body mass index, hypertension, elevated lipid and inflammatory markers, metabolic syndrome and renal failure [3–19]. For years, this disease process was thought to be due to a degenerative phenomenon by which calcium attached to the surface of the aortic valve leaflet. Understanding calcification, as the critical end-stage process which causes progression to severe stenosis and leads to poor outcomes [20], is becoming important in the results of the randomized trials for treating aortic stenosis with medical therapy. To date, these trials, including SALTIRE, Simvastatin Ezetimibe in Aortic Stenosis (SEAS), Aortic Stenosis Progression Observation: Measuring the Effects of Rosuvastatin (ASTRONOMER), have all been negative [21–23]. Over the past decade, data from several studies have confirmed that all of these traditional risk factors, including metabolic syndrome [13] and renal failure [14], which are important in the development of vascular atherosclerosis, and are also implicated in the development of CAVD [3–19]. These findings provide the foundation to study targeted strategies for medical therapy, including for example, medications for hyperlipidemia, hypertension and diabetes. There are a growing number of experimental in vivo models of calcific AS, which demonstrate primarily that lipids [24–30], diabetes [30] and renal failure [31] are important in the development of this disease. There is also increasing evidence that these cells undergo specific differentiation steps towards the development of this bone phenotype as shown in in vitro studies [32–34]. In addition, there are a growing number of retrospective [35–38] and the large-scale prospective clinical trials [21–23] testing the hypothesis that atherosclerotic CAVD may be targeted with medical therapy. The only clinical trial to date Rosuvastatin Affecting Aortic Valve Endothelium to Slow the Progression of Aortic Stenosis trial (RAAVE) was a positive study testing the hypothesis that treating elevated LDL as compared to normal LDL patients slows progression of CAVD [21]. The retrospective studies published to date are shown in Fig. 17.2 [35–38].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons CA, Masters KS, Mathieu P, O’Brien KD, Schoen FJ, Towler DA, Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–91.
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.
Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis. 1984;37:407–15.
Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol. 1985;55:744–7.
Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5.
Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol. 1987;59:998–9.
Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors–a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995–9.
Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15:865–70.
Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997;78:472–4.
Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA. Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol. 2001;24:52–5.
Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart. 1997;78:475–9.
Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol. 2001;88:690–3.
Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault M, Couet J, Pibarot P.Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol. 2006;47:2229–36.
Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101:2497–502.
Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003;91:97–9.
Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. J Am Coll Cardiol. 1997;29:630–4.
Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7 [comment].
Faggiano P, Antonini-Canterin F, Baldessin F, Lorusso R, D’Aloia A, Cas LD. Epidemiology and cardiovascular risk factors of aortic stenosis. Cardiovasc Ultrasound. 2006;4:27.
Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–32.
Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, Maurer G, Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (astronomer) trial. Circulation. 2010;121:306–14.
Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105:2260–5.
Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis. 2001;10:371–4.
Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 2003;41:1211–7.
Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065–9.
Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007;115:377–86.
Drolet MC, Roussel E, Deshaies Y, Couet J, Arsenault M. A high fat/high carbohydrate diet induces aortic valve disease in c57bl/6j mice. J Am Coll Cardiol. 2006;47:850–5.
Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine wnt signals. J Clin Invest. 2005;115:1210–20.
Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101(21):2497–502.
Blevins TL, Peterson SB, Lee EL, Bailey AM, Frederick JD, Huynh TN, Gupta V, Grande-Allen KJ. Mitral valvular interstitial cells demonstrate regional, adhesional, and synthetic heterogeneity. Cells Tissues Organs. 2008;187:113–22.
Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol. 2007;171:1407–18.
Yip CY, Chen JH, Zhao R, Simmons CA. Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix. Arterioscler Thromb Vasc Biol. 2009;29:936–42.
Antonini-Canterin F, Popescu BA, Huang G, Korcova-Miertusova R, Rivaben D, Faggiano P, Pavan D, Piazza R, Bolis A, Ciavattone A, Ruggiero A, Nicolosi GL. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? Ital Heart J. 2005;6:119–24.
Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-a reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 2002;40:1723–30 [comment].
Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O’Brien KD. Hmg coa reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125–6 [comment].
Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291–5.
Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49(5):554–61.
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97.
Newby DE, Cowell SJ, Boon NA. Emerging medical treatments for aortic stenosis: statins, angiotensin converting enzyme inhibitors, or both? Heart. 2006;92:729–34.
Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80.
Bernoulii D. Hydrodynamica Sive De Viribus et Motibus Fluidorum Commentarrii. Strasbourg: Argentoratum, St 31. 1738.
Rajamannan NM. Mechanisms of aortic valve calcification: the ldl-density-radius theory: a translation from cell signaling to physiology. Am J Physiol Heart Circ Physiol. 2010;298:H5–15.
Descartes, La Geometrie appendix: Discours de la Methode pour bien condiuire sa raison, et chercher la verite dans les sciences, 1637.
Rajamannan NM, Best P, Antonini-Canterin F, Moura LM, Saltire-raave subanalysis: a role for statins in aortic valve disease. J Am Coll Cardiol. 2011;57(14):E1317.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Rajamannan, N.M., Antonini-Canterin, F., Wachtal, K. (2014). Application of the LDL-Density-Radius Theory: The Aortic Valve. In: Rajamannan, N. (eds) Molecular Biology of Valvular Heart Disease. Springer, London. https://doi.org/10.1007/978-1-4471-6350-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-4471-6350-3_17
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-6349-7
Online ISBN: 978-1-4471-6350-3
eBook Packages: MedicineMedicine (R0)